Superworth

Pluri revenue PLUR

Sales by quarter and over the last twelve months, from 2011.

Last 12 months, to Jun 30, 2026
$1M
Latest quarter, Q4 FY26
$335K
−16% on a year earlier
Fiscal year 2026
$1M
−24% on the year before

Pluri's revenue was $1M over the twelve months to Jun 30, 2026, down 24% on a year earlier.

In its latest quarter, Q4 FY26, it was $335K, down 16% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2026$1M−24%
FY2025$1.3M+310%
FY2024$326K+14%
FY2023$287Kn/a
FY2022n/an/a
FY2020n/an/a
FY2019$54Kn/a
FY2018n/an/a
FY2016$2.8M+651%
FY2015$379K+0%
FY2014$379K−44%
FY2013$679K+40%
FY2012$485.2Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY26$335K−16%$1M
Q3 FY26$167K−61%$1.1M
Q2 FY26$198K+7%$1.3M
Q1 FY26$316K−3%$1.3M
Q4 FY25$398K+315%$1.3M
Q3 FY25$427K+501%$1M
Q2 FY25$185K+76%$678K
Q1 FY25$326K+504%$598K
Q4 FY24$96K−14%$326K
Q3 FY24$71K−18%$341K
Q2 FY24$105K+5150%$357K
Q1 FY24$54K−38%$254K

Against its peers

Companies in Healthcare nearest Pluri's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
PLURPluri$1M−24% a year
NEPHNephros$20.7M+24% a year
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech$61.9M+6% a year
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
ICCCImmucell$30.7M+8% a year
KEQUKewaunee Scientific$277.2M+5% a year
Peer median$54.5M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Pluri

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.